AstraZeneca announces tozorakimab met primary endpoint in Phase III trials

Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease, COPD, showed that tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil counts and all stages of lung function severity. Tozorakimab was generally well tolerated with a favourable safety profile. Tozorakimab is a potential first-in-class monoclonal antibody targeting interleukin-33, that inhibits the signalling of the reduced and oxidised forms of IL-33, offering the potential to both reduce inflammation and disrupt the cycle of mucus dysfunction that contribute to COPD worsening. In the OBERON and TITANIA trials, tozorakimab was studied in patients with COPD still experiencing exacerbations while on inhaled standard of care. Patients received tozorakimab 300mg or placebo on top of standard of care once every four weeks.